首页> 美国卫生研究院文献>Frontiers in Oncology >Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
【2h】

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma

机译:立体定向放射治疗胰腺癌的老年患者预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

>Introduction: Pancreatic ductal adenocarcinoma (PDAC) commonly presents later in life with a median age at diagnosis of 70 years. Unfortunately, elderly patients are significantly underrepresented in clinical trials. Stereotactic body radiation therapy (SBRT) is a promising treatment modality in this population as it has demonstrated excellent local control with minimal toxicity. We aimed to determine prognostic factors associated with outcomes in elderly patients treated with SBRT.>Materials and Methods: Elderly patients older than 70 treated with SBRT for PDAC at our institution, from 2004 to 2014 were included. Our primary endpoints included overall survival (OS) and local-progression-free survival (LPFS). Secondary endpoints included regional-progression-free survival (RPFS), distant-progression-free-survival (DPFS) and radiation toxicity. Endpoints were analyzed with the Kaplan-Meier method. The association of these survival endpoints with risk factors was studied with Cox proportional hazards models.>Results: We identified 145 patients with 146 lesions of pancreatic adenocarcinoma with a median age at diagnosis of 79 (range, 70.1–90.3). SBRT was delivered to a median dose of 36 Gy (IQR 24–36). Surgical resection was performed on 33.8% of the total patients. Median follow-up was 12.3 months (IQR 6.0–23.3 months) and the median survival for the entire cohort 14.0 months with a 2-year OS of 27%. Multivariate analysis (MVA) demonstrated surgery [p ≤ 0.0001, HR 0.29 (95% CI, 0.16–0.51)] and post-SBRT CA19-9 [p = 0.009, HR 1.0004 (95% CI, 1.0002–1.0005)] significantly associated with overall survival. Recurrent lesions [p = 0.0069, HR 5.1 (95% CI, 1.56–16.64)] and post-SBRT CA19-9 levels [p = 0.0107, HR 1.0005 (95% CI, 1.0001–1.0008)] were significantly associated with local control on MVA. For the entire cohort, 4.1% experienced acute grade 2+ toxicity, and 2% experienced late grade 2+ toxicity at 2 years.>Conclusion: This review demonstrates prognostic factors in elderly patients with PDAC treated with SBRT. We identified surgical resection and post-SBRT CA 19-9 as predictive of overall survival in this population. Additionally, we show low acute and late toxicity following SBRT in elderly patients.
机译:>简介:胰腺导管腺癌(PDAC)通常出现在生命的晚期,诊断时的中位年龄为70岁。不幸的是,老年患者在临床试验中的代表性明显不足。立体定向放射疗法(SBRT)在该人群中是一种有前途的治疗方式,因为它已显示出出色的局部控制和最小的毒性。我们的目的是确定与SBRT治疗的老年患者预后相关的预后因素。>材料和方法:我们纳入了2004年至2014年在我院接受SBRT的PDAC治疗的70岁以上老年患者。我们的主要终点包括总体生存期(OS)和无局部进展生存期(LPFS)。次要终点包括无区域无进展生存期(RPFS),无远处无进展生存期(DPFS)和放射毒性。端点采用Kaplan-Meier方法进行分析。使用Cox比例风险模型研究了这些生存终点与危险因素的相关性。>结果:我们确定了145例患有146例胰腺腺癌病变的患者,中位年龄为79岁(范围:70.1–90.3) )。 SBRT的中位剂量为36 Gy(IQR 24–36)。手术切除率为33.8%。中位随访时间为12.3个月(IQR 6.0–23.3个月),整个队列的中位生存时间为14.0个月,两年OS为27%。多变量分析(MVA)显示手术[p≤0.0001,HR 0.29(95%CI,0.16-0.51)]和SBRT后CA19-9 [p = 0.009,HR 1.0004(95%CI,1.0002-1.0005)]显着相关整体生存率。复发性病变[p = 0.0069,HR 5.1(95%CI,1.56–16.64)]和SBRT后CA19-9水平[p = 0.0107,HR 1.0005(95%CI,1.0001–1.0008)]与局部控制显着相关在MVA上。在整个队列中,有2%的患者在2年时经历了2级急性毒性反应,而2%的患者在2年后发生了2+级晚期毒性反应。>结论:该评价证明了SBRT治疗的老年PDAC患者的预后因素。我们确定了手术切除和SBRT后CA 19-9作为该人群总体生存的预测指标。此外,我们对老年患者进行SBRT后显示出较低的急性和晚期毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号